Glenmark Pharmaceuticals advanced 2% to Rs. 908 on BSE after the company received tentative approval by the United States Food & Drug Administration (USFDA) for Calcipotriene Cream, 0.005 percent.
The stock has hit a high of Rs. 929 and a low of Rs. 828.
Glenmark will market this product upon receiving final approval of its Calcipotriene Cream, 0.005% ANDA. The patents listed in the Orange Book for Dovonex® Cream are scheduled to expire on June 9, 2015.